Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic‐uremic syndrome

Rizvi, Abbas; Vesely, Sara K.; George, James N.; Chandler, Linda; Duvall, Deanna; Smith, James W.; Gilcher, Ronald O.

doi:10.1046/j.1537-2995.2000.40080896.x

Cited by 155 publications

(177 citation statements)

References 17 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…30 Despite the multiple publications assessing the efficacy of PE as treatment for TA-TMA, almost none detail non-lethal infectious complications occurring during therapy, and as such, the risk of PE-related complications in TA-TMA is typically inferred from data obtained from therapeutic PE in idiopathic TTP. [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]32,33 Our experience suggests that the risk of catheter-related sepsis in TA-TMA is greater than previously considered, especially in the presence of acute GVHD. In combination with the (absent) response rate to PE in patients with TA-TMA associated with acute GVHD, it seems difficult to justify PE as a routine therapeutic intervention for TA-TMA in this subgroup of patients.…”

Section: Discussionmentioning

confidence: 99%

Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange

Kennedy

Kearey

Bleakley

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange

Kennedy

Kearey

Bleakley

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…23 In patients following BMT, the decision to initiate plasma exchange is more difficult than in non-BMT patients because (1) the diagnosis of TTP is even less certain; (2) the vulnerability for plasma exchange complications may be greater; and (3) the response to treatment is less. [8][9][10]24 Therefore a more cautious approach to this decision may be appropriate.…”

Section: Discussionmentioning

confidence: 99%

Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes

Roy

Rizvi

Vesely

et al. 2001

Bone Marrow Transplant

105

View full text Add to dashboard Cite

Summary:The diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP) in patients following BMT are often uncertain and unsuccessful. To better understand the evaluation and management of these patients, we describe 17 patients treated with plasma exchange for a presumptive diagnosis of TTP following BMT during a 10 year period, 1989-1998. Because of the uncertainty of the diagnosis, these patients are described as having a 'TTP-like syndrome'. All 17

show abstract

“…action for patients presenting with acute TTP, it does not come without risk. In one study of 71 patients treated for clinically suspected TTP-haemolytic uraemic syndrome, 21 patients had major complications, resulting in the death of two patients; major complications included 12 systemic infections, seven episodes of catheter thrombosis and two episodes of haemorrhage after subclavian line insertion (Rizvi et al, 2000).…”

Section: Current Management Of Patientsmentioning

confidence: 99%

Rituximab in the treatment of autoimmune haematological disorders

2008

View full text Add to dashboard Cite

SummaryCurrent treatment regimens for haematological autoimmune diseases are relatively non-selective and are often associated with considerable toxicity. Recently, it has become clear that B cells play a key role in both the development and perpetuation of autoimmunity, suggesting that B-cell depletion could be a valuable treatment approach for patients with autoimmune diseases. This article reviews data supporting the use of rituximab -an anti-CD20 monoclonal antibody that specifically depletes B cells -in four key autoimmune haematological disorders: idiopathic thrombocytopenic purpura (ITP); autoimmune haemolytic anaemia (AIHA); acquired haemophilia; and thrombotic thrombocytopenic purpura (TTP). Although treatment of ITP, AIHA, acquired haemophilia and TTP with rituximab is still relatively uncommon, results from case series and small phase II trials indicate that patients of all ages can respond to rituximab, irrespective of the number or type of prior treatments that they have received. Moreover, patients with these diseases receiving rituximab experienced predominantly mild adverse events, with only a few serious adverse events reported. These data suggest that rituximab provides an effective and well-tolerated alternative treatment option for patients with ITP, AIHA, acquired haemophilia and TTP, many of whom have limited treatment choices.

show abstract

Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic‐uremic syndrome

Abstract: The morbidity and mortality of catheter placement and PE are important considerations when PE treatment for clinically suspected TTP-HUS is anticipated.

Cited by 155 publications

References 17 publications

Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange

Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange

Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes

Rituximab in the treatment of autoimmune haematological disorders

Contact Info

Product

Resources

About